Search
Home › RNS › News
Regulatory Story
Company GlaxoSmithKline PLC
TIDM GSK
Headline Director/PDMR Shareholding
Released 18:19 15-Jul-2019
Number 6040F18

RNS Number : 6040F
GlaxoSmithKline PLC
15 July 2019
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£ 16.3240

209.000

£ 16.3240

730.000

£ 16.3240

733.000

£ 16.3240

209.000

 

 

d)

Aggregated information

 

Aggregated volume Price

 

1881.000

 

 

£ 16.3240

 

e)

Date of the transaction

2019-07-12
 

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£ 16.3240

191.000

£ 16.3240

109.000

£ 16.3240

155.000

£ 16.3240

109.000

 

 

d)

Aggregated information

 

 

Aggregated volume Price

 

564.000

 

 

 

£ 16.3240

 

 

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£ 16.3240

80.000

£ 16.3240

68.000

£ 16.3240

81.000

£ 16.3240

68.000

 

 

d)

Aggregated information

 

 

Aggregated volume Price

 

297.000

 

 

 

£ 16.3240

 

 

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£ 16.3240

203.000

£ 16.3240

147.000

 

 

 

 

d)

Aggregated information

 

 

Aggregated volume Price

 

350.000

 


 

£ 16.3240

 

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£ 16.3240

86.000

£ 16.3240

181.000

£ 16.3240

150.000

£ 16.3240

86.000

 

 

d)

Aggregated information

 

 

Aggregated volume Price

 

503.000

 

 

 

£ 16.3240

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£ 16.3240

65.000

 

 

d)

Aggregated information

 

 

Aggregated volume Price

 

N/A

 

 

 

 

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£ 16.3240

105.000

£ 16.3240

82.000

£ 16.3240

102.000

 

 

d)

Aggregated information

 

Aggregated volume Price

 

289.000

 

 

£ 16.3240

 

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

 

b)

Nature of the transaction

Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$ 40.9300

76.000

$ 40.9300

78.000

 

$ 40.9300

72.000

 

 

d)

Aggregated information

 

 

Aggregated volume Price

 

226.000

 

 

 

$ 40.9300

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

 Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

 

b)

Nature of the transaction

Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$ 40.9300

428.000

 

 

d)

Aggregated information

 

 

Aggregated volume Price

 

n/a

 

 

 

 

 

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP and General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

 

b)

Nature of the transaction

Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$ 40.9300

36.000

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a


 

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms K Terrell

b)

Position/status

Chief Digital & Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

 

b)

Nature of the transaction

Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$ 40.9300

25.000

$ 40.9300

91.000

 

 

d)

Aggregated information

 

 

Aggregated volume Price

 

116.000

 

 

 

$ 40.9300

 

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDELFFKDFFBBV
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
©2009 London Stock Exchange plc. All rights reserved